To Be Discontinued Tablet Transplant

Everolimus Tablet · 312 days since initial FDA posting

FDA lists Everolimus Tablet as To Be Discontinued (Mylan Pharmaceuticals Inc., a Viatris Company).

No availability text on this FDA row.

Everolimus Tablet: To Be Discontinued

FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.

Shortage Details

Generic Name
Everolimus Tablet
Manufacturer
Mylan Pharmaceuticals Inc., a Viatris Company
Dosage Form
Tablet
Presentation
Everolimus, Tablet, 3 mg (NDC 0378-0006-85)
Package NDC
0378-0006-85

Status & Timeline

Status
To Be Discontinued
First Reported
Nov 3, 2025
Last Updated
Nov 3, 2025
Therapeutic Category
Transplant

Row fields from the FDA Drug Shortages database via openFDA.

Shortage Reason

Discontinuation of the manufacture of the drug

Nearby, Other Everolimus Shortage Records

Everolimus Tablet

Mylan Pharmaceuticals Inc., a Viatris Company

Tablet

To Be Discontinued

Everolimus Tablet

Mylan Pharmaceuticals Inc., a Viatris Company

Tablet

To Be Discontinued

Everolimus Tablet

Teva Pharmaceuticals USA, Inc.

Tablet

To Be Discontinued

Everolimus Tablet

Teva Pharmaceuticals USA, Inc.

Tablet

To Be Discontinued

Everolimus Tablet

Teva Pharmaceuticals USA, Inc.

Tablet

To Be Discontinued

Everolimus Tablet

Teva Pharmaceuticals USA, Inc.

Tablet

To Be Discontinued

FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.

← All Drug Shortages